Pentoxifylline plus prednisolone (Group 2)	Pentoxifylline alone (Group 1)	Chance of survival 	1540	1646	survival probability is higher among Group 1 patients but the difference is not statistically significant.
Pentoxifylline plus prednisolone (Group 2)	Pentoxifylline alone (Group 1)	MDF scores and MELD scores at 4 weeks	18029	18232	MDF score and MELD score were observed to be significantly lower among patients receiving PTX at the end of 4 week, as compared to those receiving PTX plus prednisolone (P < 0.05 and < 0.01 respectively)
Pentoxifylline plus prednisolone (Group 2)	Pentoxifylline alone (Group 1)	Child-Pugh, GAHS, MDF, and MELD scores at 3 months, 6 months, and 1 year	18234	18379	But there were no significant differences in MELD, MDF, Child-Pugh and GAHS score between two groups at the end of 3 months, 6 months and 1 year.
Pentoxifylline plus prednisolone (Group 2)	Pentoxifylline alone (Group 1)	Rate of morbidity and complications	16412	16484	The morbidity/complication profiles among the two groups were comparable
Pentoxifylline plus prednisolone (Group 2)	Pentoxifylline alone (Group 1)	Child-Pugh, GAHS, MDF, and MELD scores at 3 months, 6 months, and 1 year	18238	18379	there were no significant differences in MELD, MDF, Child-Pugh and GAHS score between two groups at the end of 3 months, 6 months and 1 year.
Pentoxifylline plus prednisolone (Group 2)	Pentoxifylline alone (Group 1)	Rate of morbidity and complications	16412	16495	The morbidity/complication profiles among the two groups were comparable [Table 2].
